Evaxion A/S announced on October 3, 2025, that it will present new biomarker and immune data for its lead asset, EVX-01, at a poster session during the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The meeting is scheduled to take place in National Harbor from November 5-9, 2025.
EVX-01 is a personalized cancer vaccine designed with Evaxion’s AI-Immunology platform, currently undergoing evaluation as a treatment for advanced melanoma. This new data stems from the ongoing Phase 2 trial.
The presentation at SITC will complement the two-year clinical efficacy data from the same trial, which is scheduled for an oral presentation at the ESMO 2025 congress on October 17, 2025. Both datasets contribute to the growing body of evidence supporting EVX-01.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.